Long-term blood pressure control and the risk of dementia
Yingxian Sun is Director of the Department of Cardiology at The First Affiliated Hospital of China Medical University in Shenyang, China, and Director of the Cardiovascular Disease Research Institute of China Medical University. He is a professor, chief physician, and doctoral supervisor. He received his medical training at China Medical University.
Long-term BP control for dementia prevention awaits ESC 2026 trial readout; leaves open whether sustained lowering alters cognitive outcomes.
Key result
Long-term blood pressure control effects on the risk of dementia are currently pending results from a late-breaking trial at ESC Congress 2026.
Expert reaction lands here the moment CRHCP reports.
The China Rural Hypertension Control Project (CRHCP) is a cluster-randomized trial of ~34,000 patients in 326 rural Chinese villages testing whether nonphysician community health workers can deliver intensive BP-lowering (target <130/80 mmHg) to reduce cardiovascular events and dementia. Over 48 months, the intervention reduced CVD by 25-33%, all-cause mortality by 10-15%, and all-cause dementia by 15% compared to usual care. The trial has generated strong expert enthusiasm, with commentators calling the dementia findings "world-changing" and the first definitive randomized evidence for dementia prevention through BP control.
Absolute Event Rate: 0% vs 0%
Yingxian Sun (Thu,) reported a other. Long-term blood pressure control effects on the risk of dementia are currently pending results from a late-breaking trial at ESC Congress 2026.